Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

tocilizumab

tocilizumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Actemra INJECTION, SUBCUTANEOUS 162 mg/0.9 mL      
Actemra SOLUTION, INTRAVENOUS 20 mg/mL      
Tofidence SOLUTION, INTRAVENOUS 20 mg/mL      
Comments:

Cytokine Release Syndrome (CRS): Tocilizumab inpatient use is restricted to oncology/hematology providers. 

 

COVID-19:  Due to the potential role in treatment of COVID-19 in patients with evidence of cytokine release, tocilizumab may be utilized in select patients when prescribed by Infectious Diseases or Pediatric Critical Care following Huntsville Hospital's Criteria for Use.  Due to limited supply, availability of this medication is not guaranteed.

Other Indications: Tocilizumab is as restricted to outpatient use.

 

TOFIDENCE: Therapeutically equivalent to Actemra for treatment of COVID-19 and CRS. The most cost-effective product may be utilized. Tofidence use in other indications is pending further review by P&T.

 

 

Actemra medication guide

 

 

Reviewed: December 2023 (Tofidence)

 

Updated: March 2024 (Inpatient Use, Tofidence)

 

Tocilizuymab-bavi (Tofidence)

 

Tocilizumab-bavi (Tofidence) CRS Update

Last updated: May. 6, 2024






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved